anti-cancer agent News
-
BriaCell Secures License for a Promising Novel Anti-Cancer Agent
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces that it has secured an exclusive license from University of Maryland, Baltimore County (UMBC) to develop and commercialize Soluble CD80 (sCD80) as a biologic agent for the ...
-
Onconova Therapeutics to Present at the Upcoming RHK Capital Disruptive Growth Conference
Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that it will participate in the RHK Capital Disruptive Growth Conference being held in the offices of Reed Smith in New York, NY on December 5-6, 2022. Mark Guerin, Chief Operating Officer & Chief Financial Officer, will ...
-
Onconova Therapeutics Announces Acceptance Of Abstract For Publication At The ASCO Annual Meeting
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the acceptance of an abstract for publication at the American Society of Clinical Oncology (ASCO) Annual Meeting. Details on the abstract are provided below. Abstract Title: Narazaciclib’s kinase inhibitory ...
-
Onconova Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating in-person in the Ladenburg Thalmann 2022 Healthcare Conference, which is taking place at the Sofitel Hotel in New York, NY. Steven Fruchtman, M.D., ...
-
Taiho Oncology Announces Updated Efficacy and Safety Data for Futibatinib in Cholangiocarcinoma at 2022 ASCO Annual Meeting
PRINCETON, N.J., June 3, 2022 – Taiho Oncology, Inc. announced today updated results of the Phase 2 FOENIX-CCA2 trial of futibatinib, confirming results observed in an earlier analysis. The trial was conducted in patients with locally advanced or metastatic unresectable intrahepatic (inside the liver) cholangiocarcinoma (iCCA) harboringFGFR2 gene rearrangements including fusions. These data ...
-
Onconova Therapeutics Announces Key Management Promotions
Mark Guerin promoted to Chief Operating Officer and Chief Financial Officer Dr. Adar Makovski Silverstein promoted to Senior Director and Head of Corporate Development Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Mark Guerin was appointed Chief ...
-
U.S. Food and Drug Administration (FDA) Accepts for Priority Review Taiho Oncology’s New Drug Application for Futibatinib for Cholangiocarcinoma
PRINCETON, N.J., MARCH 30, 2022 – Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review the New Drug Application (NDA) for futibatinib in the treatment of patients with previously treated locally advanced or metastatic cholangiocarcinoma (CCA) harboringFGFR2 gene rearrangements, including ...
-
LIXTE Biotechnology Holdings to Present at Planet MicroCap Showcase: VIRTUAL 2022 Investor Conference
LIXTE Biotechnology Holdings, Inc. (Nasdaq:LIXT) today announced it will be presenting at the Planet MicroCap Showcase: VIRTUAL 2022 investor conference Wednesday, December 7, 2022 at 3:30 p.m. EST/12:30 p.m. PST. John S. Kovach, M.D., founder and CEO of LIXTE, will host the presentation. Dr. Kovach, with his team, will be answering questions at the conclusion. To access the presentation, ...
-
NIH investigators find link between DNA damage and immune response
Researchers offer the first evidence that DNA damage can lead to the regulation of inflammatory responses, the body's reaction to injury. The proteins involved in the regulation help protect the body from infection. The study, performed by scientists at the National Institute of Environmental Health Sciences (NIEHS), which is part of the National Institutes of Health, is one of the first studies ...
-
Drug Combination Meets Survival Endpoint in Phase III Pivotal Trial Involving Participants With Refractory Metastatic Colorectal Cancer
Results from the primary analysis of the SUNLIGHT trial to be presented at an upcoming scientific conference Paris - September 12, 2022– Servier, Taiho Oncology, Inc., and Taiho Pharmaceutical Co., Ltd., announced today that the investigational combination of trifluridine/tipiracil plus bevacizumab showed a statistically significant improvement in the primary endpoint of overall survival ...
-
Onconova Therapeutics Announces Abstract At The ASCO Annual Meeting Highlighting Narazaciclib’s Differentiated Inhibitory And Improved Safety Profile In Preclinical Models
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the publication of an abstract at the American Society of Clinical Oncology (ASCO) Annual Meeting. Featured in the abstract are preclinical data from in vitro and cell-based assays that demonstrate how ...
-
Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung Cancer
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Cancer Research UK recently completed patient enrollment in the ongoing Phase 1 clinical trial of VAC2, an allogeneic cancer vaccine product candidate, for the treatment of non-small cell lung cancer ...
-
Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine
OXFORD, United Kingdom, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Cancer Research UK, Vaccitech plc (Nasdaq: VACC) and the Ludwig Institute for Cancer Research (Ludwig), today announce the first patient dosed in the MAGE trial, which is testing a novel immunotherapeutic, VTP-600, in patients with the most common type of lung cancer. The phase I/IIa trial is expected to enroll approximately 86 people who ...
-
FDA Approves Taiho’s LYTGOBI® (futibatinib) Tablets for Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma
LYTGOBI (pronounced “light-GOH-bee”) delivered an objective response rate of 42% and median duration of response of 9.7 months in the primary analysis of the pivotal clinical trial. LYTGOBI covalently binds to FGFR2 and inhibits the signaling pathway. The other approved FGFR inhibitors are reversible ATP-competitive inhibitors. LYTGOBI previously received breakthrough, orphan drug ...
-
PsiOxus Therapeutics updates agreement with Bristol-Myers Squibb to advance their clinical stage immuno-oncology collaboration
OXFORD, UK – 7 April 2021: PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an updated agreement to advance its clinical collaboration with Bristol Myers Squibb (NYSE: BMY) to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ tumor re-engineering platform, in combination with Bristol Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo® ...
-
Lauren Sciences LLC awarded second grant for LAUR-401 from Voices Against Brain Cancer
New York, New York, February 7, 2017 -- Lauren Sciences LLC, the private New York biotechnology company developing transformative V-Smart™ Nanomedicines for brain diseases, today announced the award of its second grant from Voices Against Brain Cancer (VABC). VABC grant will support Lauren Sciences continued development of LAUR-401, its novel V-Smart™ Nanomedicine for Glioblastoma ...
-
NIH investigators find link between DNA damage and immune response
Researchers offer the first evidence that DNA damage can lead to the regulation of inflammatory responses, the body's reaction to injury. The proteins involved in the regulation help protect the body from infection. The study, performed by scientists at the National Institute of Environmental Health Sciences (NIEHS), which is part of the National Institutes of Health, is one of the first studies ...
-
Dyve Biosciences Announces Research and Development Collaboration with Moffitt Cancer Center
CAMARILLO, Calif. and TAMPA, Fla., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of clinical assets, today announced a joint, two-year research collaboration with Moffitt Cancer Center. The collaboration will study Dyve’s systemic buffering agent, ...
-
Onconova Therapeutics Announces Updated Data from Investigator-sponsored Phase 1/2a Trial Evaluating Rigosertib in Combination with Nivolumab in Advanced KRAS-mutated Non-Small Cell Lung Cancer at the ESMO Congress 2022
Data show an early signal of efficacy in an extensively pre-treated population with 1 complete response and 2 partial responses achieved in 14 evaluable patients Responses achieved in patients with 3 distinct and different KRAS mutations, confirming the MOA of rigosertib being KRAS+ agnostic 4 of 14 (29%) evaluable patients demonstrated disease control The combination of rigosertib and ...
-
Lauren Sciences awarded grant by Voices Against Brain Cancer to develop V-Smart Nanomedicine for GBM
New York, New York, June 30, 2015 -- Lauren Sciences LLC, the private New York biotechnology company developing breakthrough V-Smart™ Nanomedicines for brain diseases, announced today the award of a grant by Voices Against Brain Cancer (VABC). VABC funding will support the development of a V-Smart™ for glioblastoma multiforme (GBM). The future success of V-Smart™ for GBM should ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you